Search Results 31-40 of 18881 for B cell lymphomas
It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma. Venetoclax ...
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Relapse in Aggressive B-cell Non-Hodgkin Lymphomas · Overview · Participation eligibility.
Clinical Trials · Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) · More about research at Mayo Clinic · Mayo ...
Learn about this type of cancer that starts in the white blood cells and affects the skin. Treatment options include surgery, radiation and chemotherapy.
Then the cells go back into the body. There they find and destroy the non-Hodgkin lymphoma cells. CAR-T cell therapy might be an option for certain types of B- ...
A Study of Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell ...
It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with follicular lymphoma. Venetoclax ...
— Hong Qin, M.D., Ph.D. CAR -T cell therapy has shown potential in achieving remission in some B-cell lymphomas and leukemias. Yet ...
The purpose of this study is to evaluate the safety and tolerability of STP938 as a single agent in adult subjects with R/R B-cell and T-cell lymphomas.
Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma · Share · Facebook · Twitter.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.